ProCE Banner Activity

Carfilzomib/Lenalidomide/Low-Dose Dexamethasone in MM With Early Progression: ASPIRE Subgroup Analysis

Slideset Download
Conference Coverage
Addition of carfilzomib to lenalidomide/low-dose dexamethasone improved PFS and ORR in patients with MM who relapsed within 1 year after first previous therapy or transplantation.

Released: June 14, 2016

Expiration: June 13, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals